CHD7 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of the chromodomain helicase DNA binding protein 7 (CHD7). CHD7 is a member of the CHD family of proteins, which are characterized by the presence of chromodomains, helicase domains, and DNA-binding domains. These proteins are involved in chromatin remodeling, a critical process for regulating gene expression by altering the structure of chromatin to either promote or inhibit access to genetic information. CHD7, in particular, plays a pivotal role in the regulation of gene expression during development, influencing processes such as cellular differentiation, proliferation, and the establishment of cell identity.
Structurally, CHD7 inhibitors can vary widely and may include small molecules, peptides, or larger biomolecules engineered to bind to specific domains of the CHD7 protein. These inhibitors typically interact with the ATPase/helicase domain of CHD7, which is essential for its chromatin remodeling activity. By inhibiting this domain, these compounds prevent CHD7 from utilizing ATP to alter chromatin structure, thereby impeding its ability to modulate gene expression. The study of CHD7 inhibitors is crucial for understanding the functional mechanisms by which CHD7 influences chromatin dynamics and gene regulation. By examining how these inhibitors affect CHD7 activity, researchers can gain insights into the broader implications of chromatin remodeling on cellular functions such as transcriptional regulation, DNA repair, and replication. Research into CHD7 inhibitors also sheds light on the intricate balance of chromatin states that dictate cellular behavior and development, providing a deeper understanding of the role of CHD7 in maintaining the epigenetic landscape of cells.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
Romidepsin is an inhibitor of histone deacetylase which can affect the acetylation status of histones, thereby influencing chromatin structure and CHD (chromodomain helicase DNA-binding) function. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $214.00 $247.00 $1463.00 | 2 | |
Mocetinostat is a histone deacetylase inhibitor that can modify the acetylation status of histones and influence the chromatin structure and CHD (chromodomain helicase DNA-binding) activity. | ||||||
BIX01294 hydrochloride | 1392399-03-9 | sc-293525 sc-293525A sc-293525B | 1 mg 5 mg 25 mg | $37.00 $112.00 $408.00 | ||
BIX-01294 is an inhibitor of G9a and GLP histone methyltransferases that can affect histone methylation, thereby influencing the chromatin remodeling activities of CHD (chromodomain helicase DNA-binding). | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor influencing CHD (chromodomain helicase DNA-binding) by preventing protein degradation, leading to increased CHD (chromodomain helicase DNA-binding) levels and altered cellular functions. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Inhibitor of MDM2, indirectly affecting CHD (chromodomain helicase DNA-binding) by stabilizing p53 and influencing downstream pathways related to CHD (chromodomain helicase DNA-binding) activity. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
Inhibitor of p300/CBP histone acetyltransferase, indirectly impacting CHD (chromodomain helicase DNA-binding) by modulating acetylation levels and chromatin structure. | ||||||
EPZ6438 | 1403254-99-8 | sc-507456 | 1 mg | $66.00 | ||
Specific EZH2 inhibitor affecting CHD (chromodomain helicase DNA-binding) indirectly by targeting the Polycomb Repressive Complex 2 (PRC2) and altering chromatin structure. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
Dual inhibitor of lysine-specific demethylase 1 (LSD1) and histone deacetylases, indirectly impacting CHD (chromodomain helicase DNA-binding) by modulating histone modifications. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Topoisomerase I inhibitor that indirectly modulates CHD (chromodomain helicase DNA-binding) by inducing DNA damage and influencing chromatin structure, affecting CHD (chromodomain helicase DNA-binding) binding and activity. | ||||||